What are the dosing recommendations, common adverse effects, contraindications, and alternative therapies for trazodone when used to treat major depressive disorder and insomnia?

Trazodone for Major Depressive Disorder and Insomnia

Dosing Recommendations

For major depressive disorder, trazodone requires 150–300 mg/day to achieve antidepressant efficacy; lower doses (25–50 mg) used for insomnia alone are insufficient to treat depression. 1, 2, 3, 4

Depression Treatment Dosing

• Start at 150 mg/day and titrate to 150–300 mg/day for full antidepressant effect 1, 3, 4
• Maximum tolerated doses in elderly patients are 300–400 mg/day, while younger patients may tolerate up to 600 mg/day 5
• The once-daily formulation maintains effective blood levels for 24 hours while avoiding concentration peaks associated with side effects 3

Insomnia-Only Dosing (Off-Label)

• The American Academy of Sleep Medicine explicitly recommends AGAINST using trazodone for primary insomnia because trials showed only minimal benefit (≈10 min reduction in sleep latency, ≈8 min reduction in wake after sleep onset) with no improvement in subjective sleep quality, and harms outweigh benefits 1
• When used off-label despite recommendations, typical doses are 25–150 mg at bedtime, taken at least 1 hour before sleep on an empty stomach 1, 6

Depression with Comorbid Insomnia

• When depression and insomnia coexist, use full antidepressant dosing (150–300 mg/day); the 50 mg dose commonly prescribed is inadequate for treating the underlying mood disorder 1, 2
• Alternatively, combine a full-dose antidepressant (e.g., SSRI) with low-dose trazodone (50–100 mg) specifically for sleep augmentation 1

---

Common Adverse Effects

The most frequent side effects are somnolence (daytime drowsiness), headache, dizziness, and dry mouth (xerostomia). 3, 4

Frequent Effects

• Drowsiness is the most commonly reported adverse effect and occurs in the majority of patients 5, 3
• Headache affects approximately 30% of patients 1
• Dizziness and orthostatic hypotension are common, especially in elderly patients and those with cardiovascular disease 1, 5, 3

Serious but Rare Effects

• Priapism (prolonged, painful erection >4 hours) is a medical emergency requiring immediate care; it led to treatment discontinuation in clinical studies 1
• Cardiac arrhythmias and QT interval prolongation may occur, particularly in patients with pre-existing cardiovascular disease 5, 3
• Orthostatic hypotension poses fall risk, especially in older adults 1, 5, 3

Tolerability Profile

• Trazodone has minimal anticholinergic activity compared to tricyclic antidepressants, resulting in lower rates of constipation, urinary retention, and dry mouth 2, 5, 3, 4
• Low risk of weight gain and sexual dysfunction compared to SSRIs 3, 4
• In elderly patients, adverse events occurred in approximately 75% of participants (vs. 65% on placebo) 1

---

Contraindications and Precautions

Absolute Contraindications

• History of priapism on any medication 1
• Concurrent use with MAO inhibitors (standard antidepressant contraindication) 3

Use with Extreme Caution

• Compromised respiratory function (asthma, COPD, sleep apnea) – trazodone can worsen respiratory depression 1
• Hepatic impairment or heart failure – requires dose reduction and close monitoring 1, 5
• Severe cardiovascular disease – increased risk of arrhythmias and orthostatic hypotension 5, 3
• Elderly patients – higher sensitivity to sedation, falls, and cognitive impairment; consider dose reduction 1

Pregnancy and Nursing

• Avoid in pregnancy and nursing 1

Drug Interactions

• Avoid alcohol and other CNS depressants due to additive sedative effects 1
• Combining with opioids (e.g., hydrocodone) carries FDA black box warning for serious effects including respiratory depression and death; use lowest doses with close monitoring 1
• Combining with benzodiazepines increases oversedation risk 1
• Monitor for additive sedation when combined with other antidepressants (e.g., vilazodone, mirtazapine) 1

---

Alternative Therapies

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I must be offered as the initial treatment for chronic insomnia before any medication, as it provides superior long-term efficacy with sustained benefits after discontinuation. 1, 7

• Core components include stimulus control therapy, sleep restriction therapy, relaxation techniques, and cognitive restructuring 1, 7
• Can be delivered via individual therapy, group sessions, telephone, web-based modules, or self-help books 1, 7
• Sleep hygiene education alone is insufficient but should be combined with other CBT-I components 1, 7

Preferred Pharmacologic Alternatives for Insomnia

For Sleep-Maintenance Insomnia

• Low-dose doxepin 3–6 mg – reduces wake after sleep onset by 22–23 minutes, has minimal anticholinergic effects at hypnotic doses, and carries no abuse potential 1, 7
• Suvorexant 10 mg – orexin receptor antagonist that reduces wake after sleep onset by 16–28 minutes with lower cognitive impairment risk 1, 7

For Sleep-Onset Insomnia

• Ramelteon 8 mg – melatonin receptor agonist with no abuse potential, preferred when substance-use history exists 1, 7
• Zaleplon 10 mg (5 mg in elderly) – very short half-life for rapid sleep initiation with minimal next-day sedation 1, 7
• Zolpidem 10 mg (5 mg in elderly) – shortens sleep-onset latency by ≈25 minutes 1, 7

For Combined Sleep-Onset and Maintenance Insomnia

• Eszopiclone 2–3 mg (1 mg in elderly) – increases total sleep time by 28–57 minutes with moderate-to-large improvement in sleep quality 1, 7

Alternative Antidepressants for Depression with Insomnia

When treating major depressive disorder with comorbid insomnia, sedating antidepressants are appropriate first-line options. 2

• Mirtazapine – sedating antidepressant with cardiovascular safety, useful when appetite stimulation is beneficial 2
• Doxepin 25 mg – when used for depression (not just insomnia), provides both antidepressant and sleep benefits 2
• Amitriptyline 25 mg – more anticholinergic side effects than other options 2

Medications Explicitly NOT Recommended

• Over-the-counter antihistamines (diphenhydramine) – lack efficacy data, cause anticholinergic effects, tolerance develops within 3–4 days 1, 7
• Benzodiazepines (lorazepam, clonazepam) – high risk of dependence, falls, cognitive impairment, and dementia 1, 7
• Antipsychotics (quetiapine, olanzapine) – weak evidence for insomnia, significant metabolic risks 1, 7
• Melatonin supplements – only ≈9 min reduction in sleep latency, insufficient evidence 1, 7
• Herbal supplements (valerian) – insufficient evidence of efficacy 1, 7

---

Treatment Algorithm

For Primary Insomnia (Without Depression)

1. Initiate CBT-I immediately as standard of care 1, 7
2. If CBT-I insufficient after 4–8 weeks, add FDA-approved hypnotic (NOT trazodone):
   • Sleep-maintenance: low-dose doxepin 3–6 mg or suvorexant 10 mg 1, 7
   • Sleep-onset: ramelteon 8 mg or zaleplon 10 mg 1, 7
   • Combined: eszopiclone 2–3 mg 1, 7
3. Reassess after 1–2 weeks for efficacy and adverse effects 1, 7
4. Use lowest effective dose for shortest duration (≤4 weeks for acute insomnia) 1, 7

For Major Depressive Disorder with Insomnia

1. Start full-dose antidepressant therapy (150–300 mg/day trazodone OR alternative SSRI/SNRI) 2, 3, 4
2. Simultaneously initiate CBT-I 1, 7, 2
3. If insomnia persists on adequate antidepressant dose, add low-dose sedating agent (e.g., trazodone 50–100 mg if on SSRI, or low-dose doxepin 3–6 mg) 1, 2
4. Monitor for treatment response at 2–4 weeks and adjust accordingly 2, 3

For Major Depressive Disorder Without Insomnia

1. Use standard antidepressant dosing (150–300 mg/day trazodone) 3, 4
2. Monitor for efficacy and tolerability 3, 4
3. Consider alternative antidepressants if inadequate response or intolerable side effects 3, 4

---

Critical Safety Warnings

• All patients must be counseled about complex sleep behaviors (sleep-driving, sleep-walking) and instructed to discontinue immediately if these occur 1
• Patients should rise slowly from seated/supine positions to minimize orthostatic hypotension and dizziness 1
• Any prolonged erection >4 hours requires immediate emergency care 1
• Avoid combining multiple sedating medications due to additive respiratory depression, cognitive impairment, and fall risk 1
• Regular follow-up every few weeks initially to assess effectiveness, side effects, and ongoing need 1
• Taper gradually when discontinuing to avoid withdrawal symptoms 1